Fampridine: the MS drug now on the NHS and how it helps patients walk

For thousands of people in England living with multiple sclerosis, a drug that has been available elsewhere in the world for more than a decade has just become available on the NHS. Fampridine, a twice-daily tablet that improves the way nerve signals travel along damaged pathways, has been approved for patients whose MS affects their ability to walk. Health officials estimate that as many as 5,000 people could be eligible.

Multiple sclerosis is a condition in which the immune system attacks the protective coating around nerve fibres, called myelin, disrupting the electrical signals that travel between the brain and the rest of the body. One of the most common and disruptive consequences is a reduced ability to walk, whether that means slower pace, more fatigue, or a shorter distance before needing to rest.

Fampridine does not repair the underlying nerve damage or slow the course of MS itself. Instead, it works by partially blocking potassium channels on damaged nerve fibres, which helps the fibres conduct electrical impulses more effectively even where the myelin sheath has been worn away. In practice, that can translate into a measurably faster or steadier walking speed for some patients.

The drug has a long history outside the UK. It was approved in the United States in 2010 under the brand name Ampyra, and later authorised in the European Union as Fampyra. British patients who could afford to pay privately, or who accessed it through specific trial or compassionate-use schemes, have in some cases been using it for years. Its arrival on the NHS formulary in England means it is now available through a standard prescribing pathway rather than private payment.

Eligibility is not universal among the roughly 150,000 people in the UK who live with MS. Clinical trial data has shown that only a subset of patients, generally those who can already walk unaided but with noticeable difficulty, respond meaningfully to the drug. NHS prescribing guidance is expected to require a trial period, with continued prescriptions dependent on a patient demonstrating measurable improvement in walking speed within the first weeks of treatment.

That trial-and-response model reflects a broader pattern in MS symptom management: because the disease affects people so differently, treatments that help one patient may do little for another. Fampridine's approval adds a symptomatic option to a treatment landscape that, in recent years, has focused heavily on disease-modifying therapies designed to reduce the frequency of relapses rather than manage day-to-day symptoms like mobility.

Cost has historically been the main obstacle to fampridine's wider use in publicly funded health systems. Because the drug must be taken indefinitely to maintain its effect, and because its benefit is confined to a subset of patients, cost-effectiveness reviews in various countries have taken years to conclude the price was justified relative to the improvement in mobility and quality of life it delivers.

For patients whose mobility is central to their independence, even modest walking improvements can carry outsized importance, affecting whether someone can continue working, manage a household, or move around their community without assistance. MS charities have long pushed for wider access to symptom-focused treatments alongside the disease-modifying drugs that dominate MS research funding.

The approval also highlights the layered nature of MS care in England, where relapse-preventing therapies, symptom management, physiotherapy, and rehabilitation support are typically coordinated through neurology teams rather than delivered as a single treatment. Fampridine is expected to be added to that toolkit for eligible patients rather than replace any existing element of their care.

Rollout is expected to be gradual as NHS trusts update local prescribing protocols and neurology teams identify patients likely to benefit. Officials have said the drug will be available through specialist MS services rather than general practice, meaning patients will need a referral or an existing relationship with a neurology team to be assessed.

For a condition with no cure and few symptomatic treatments backed by strong trial evidence, a therapy that can measurably improve walking for even a fraction of patients represents a meaningful, if incremental, addition to what is available. Whether the roughly 5,000 eligible patients see life-changing benefit, as NHS officials have described it, will become clearer as prescribing data accumulates over the coming year.